Mr. Market has become quite enthusiastic about Eli Lilly, bidding its shares to approximately $1,036 1 and its market capitalization to a staggering $800 billion 3. As a patient
Eli Lilly & Co presents what appears to be the pharmaceutical success story of the decade—a company riding the transformative wave of GLP-1 obesity therapeutics to an $800 billion
The macro environment for Eli Lilly & Co represents a convergence of structural tailwinds and increasingly formidable headwinds that collectively suggest a transition from unimpeded growth to policy-constrained value. At
